A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

拓扑替康 医学 神经母细胞瘤 联合疗法 耐火材料(行星科学) 中性粒细胞减少症 环磷酰胺 粘膜炎 队列 不利影响 肿瘤科 胃肠病学 毒性 内科学 外科 化疗 细胞培养 遗传学 天体生物学 生物 物理
作者
Steven G. DuBois,Chitose Ogawa,Lucas Moreno,Yaël P. Mossé,Matthias Fischer,Anne L. Ryan,Kieuhoa T. Vo,Bram De Wilde,Alba Rubio‐San‐Simón,Margaret E. Macy,Lisa Howell,Suzanne Shusterman,Nadège Corradini,Roberto Luksch,Isabelle Aerts,Jennifer H. Foster,Brian Weiss,C Karthik,Eunice Yuen,Emin Avşar
出处
期刊:Cancer [Wiley]
卷期号:131 (4)
标识
DOI:10.1002/cncr.35751
摘要

Abstract Background This study evaluated the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine as monotherapy and combination therapy in children with relapsed/refractory neuroblastoma. Methods Patients aged 2–21 years who had relapsed/refractory neuroblastoma were enrolled. LY3295668 erbumine was evaluated at two dose levels (12 and 15 mg/m 2 ) and administered orally twice daily continuously as monotherapy and in combination with intravenous topotecan and cyclophosphamide in 28‐day cycles. Results Twenty‐five patients were treated. No dose‐limiting toxicity occurred in monotherapy; one patient had dose‐limiting toxicities in the combination therapy cohort (grade 3 mucositis and grade 4 neutropenia). The recommended phase 2 dose for both monotherapy and combination therapy was 15 mg/m 2 . Twenty‐two patients (88%) had one or more treatment‐related adverse event(s) (TRAEs), and 18 (72%) experienced grade ≥3 TRAEs. Myelosuppression was the most common high‐grade TRAE observed in the combination therapy cohort. At both dose levels, steady‐state plasma concentrations exceeded xenograft 90% inhibitory concentration levels. In the monotherapy cohort, one patient had a minor response, and one patient had stable disease, both continuing for >12 months. In the combination therapy cohort, two patients had a partial response, two had a minor response, and six had stable disease. Overall, the response rate, according to New Approaches to Neuroblastoma Therapy version 2.0 criteria, was 8%, and the disease control rate was 52%. Conclusions LY3295668 erbumine had a manageable safety profile as monotherapy and in combination therapy. Although proof‐of‐concept clinical responses were observed, future studies with biomarker‐selected populations and/or novel combinations may yield higher response rates with Aurora kinase A inhibition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
月亮褪色了完成签到 ,获得积分20
1秒前
萱棚完成签到 ,获得积分10
1秒前
2秒前
Cao完成签到 ,获得积分10
2秒前
ENG完成签到,获得积分10
4秒前
alick完成签到,获得积分10
6秒前
刘刘完成签到,获得积分10
7秒前
Tom完成签到,获得积分10
8秒前
Villanellel发布了新的文献求助10
9秒前
程艳完成签到 ,获得积分10
10秒前
MINGHUI完成签到,获得积分10
11秒前
11秒前
子车半烟完成签到,获得积分10
11秒前
13秒前
淳于安筠完成签到,获得积分10
13秒前
雨晴完成签到,获得积分10
16秒前
jbq发布了新的文献求助10
16秒前
joshar完成签到,获得积分10
16秒前
17秒前
量子星尘发布了新的文献求助10
19秒前
blueblue完成签到,获得积分10
21秒前
落后秋烟完成签到,获得积分10
23秒前
大橙子发布了新的文献求助10
24秒前
LMY完成签到 ,获得积分10
24秒前
Betty完成签到 ,获得积分10
24秒前
NexusExplorer应助jbq采纳,获得10
25秒前
渔渔完成签到 ,获得积分10
25秒前
26秒前
Tangyartie完成签到 ,获得积分10
26秒前
skbkbe完成签到 ,获得积分10
27秒前
陈俊雷完成签到 ,获得积分0
28秒前
阿苗完成签到,获得积分10
29秒前
神勇的天问完成签到 ,获得积分10
30秒前
30秒前
advance完成签到,获得积分10
30秒前
李cc发布了新的文献求助10
31秒前
蒋念寒发布了新的文献求助10
32秒前
Sindy完成签到,获得积分10
32秒前
彭于晏应助HH采纳,获得30
34秒前
34秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022